The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Bluebird bio Inc (NASDAQ: BLUE) closed at $0.71 up 0.54% from its previous closing price of $0.71. In other words, the price has increased by $0.54 from its previous closing price. On the day, 12.67 million shares were traded. BLUE stock price reached its highest trading level at $0.77 during the session, while it also had its lowest trading level at $0.68.
Ratios:
For a deeper understanding of Bluebird bio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.
Morgan Stanley Upgraded its Underweight to Equal-Weight on December 08, 2023, whereas the target price for the stock was revised from $3 to $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 03 ’24 when Klima Thomas J sold 3,834 shares for $0.97 per share. The transaction valued at 3,726 led to the insider holds 121,006 shares of the business.
Colvin Richard A sold 6,770 shares of BLUE for $10,342 on Mar 01 ’24. The Chief Medical Officer now owns 118,368 shares after completing the transaction at $1.53 per share. On Mar 04 ’24, another insider, Obenshain Andrew, who serves as the President and CEO of the company, sold 6,095 shares for $1.53 each. As a result, the insider received 9,311 and left with 279,998 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 136673360 and an Enterprise Value of 206944304. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.29 while its Price-to-Book (P/B) ratio in mrq is 0.34. Its current Enterprise Value per Revenue stands at 9.525 whereas that against EBITDA is -1.57.
Stock Price History:
Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is -31.00%, while the 200-Day Moving Average is calculated to be -54.35%.
Shares Statistics:
For the past three months, BLUE has traded an average of 6.29M shares per day and 11555810 over the past ten days. A total of 192.74M shares are outstanding, with a floating share count of 191.55M. Insiders hold about 1.51% of the company’s shares, while institutions hold 42.27% stake in the company. Shares short for BLUE as of 1722384000 were 31126586 with a Short Ratio of 4.95, compared to 1719532800 on 30713131. Therefore, it implies a Short% of Shares Outstanding of 31126586 and a Short% of Float of 17.24.
Earnings Estimates
Current recommendations for the stock of the company come from 10.0 analysts. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.29 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.27 and -$2.26 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$1.42, with 11.0 analysts recommending between -$0.95 and -$2.29.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $9.66M this quarter.It ranges from a high estimate of $15.51M to a low estimate of $7.8M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $62kFor the next quarter, 9 analysts are estimating revenue of $19.04M. There is a high estimate of $22M for the next quarter, whereas the lowest estimate is $18.1M.
A total of 12 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $47.74M, while the lowest revenue estimate was $29M, resulting in an average revenue estimate of $32.32M. In the same quarter a year ago, actual revenue was $3.6MBased on 12 analysts’ estimates, the company’s revenue will be $103.41M in the next fiscal year. The high estimate is $167.5M and the low estimate is $64M.
